Mark A. Varney
Fondatore presso Neurolixis, Inc.
Posizioni attive di Mark A. Varney
Società | Posizione | Inizio | Fine |
---|---|---|---|
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Direttore/Membro del Consiglio | - | - |
Fondatore | - | - |
Storia della carriera di Mark A. Varney
Precedenti posizioni note di Mark A. Varney
Società | Posizione | Inizio | Fine |
---|---|---|---|
RESPIRERX PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 30/01/2006 | 22/03/2013 |
Contatto Relazioni con gli Investitori | 16/06/2011 | 22/03/2013 | |
Public Communications Contact | 29/07/2010 | 22/03/2013 | |
Presidente | 30/01/2006 | 22/03/2013 | |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/06/2004 | 01/01/2006 |
BIONOMICS LIMITED | Corporate Officer/Principal | 01/06/2004 | 01/06/2004 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/09/1999 | 01/04/2003 |
Sibia Neurosciences, Inc. | Corporate Officer/Principal | 01/10/1994 | 01/09/1999 |
Formazione di Mark A. Varney
University of Surrey | Undergraduate Degree |
University of Oxford | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 6 |
Regno Unito | 3 |
Australia | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Director/Board Member | 2 |
Investor Relations Contact | 1 |
Settori
Health Technology | 6 |
Consumer Services | 3 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
RESPIRERX PHARMACEUTICALS INC. | Health Technology |
MERCK & CO., INC. | Health Technology |
BIONOMICS LIMITED | Health Technology |
Aziende private | 3 |
---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |
Sibia Neurosciences, Inc. | Health Technology |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Mark A. Varney
- Esperienza